Abu Jalloh is Associate Director of Corporate Development at Scripps Research, where he is responsible for evaluating novel technologies’ technical strength, patentability, and commercial readiness. For early-stage technologies, he is the primary liaison between inventors and potential funders, operators, and/or external founders.Prior to his role at Scripps Research, Abu worked at 3 biotech companies – at the time, two pre-IPO startups (CUE & GRTS) and one mid-sized establishment (FATE). At Cue Biopharma, he developed and led efforts to generate novel and comprehensive assays for T cell-engagers – projects that became the basis for the S-1 filing. He later established optimal workflows for TCR identification and validation for a newly formed TCR Department at Gritstone Bio (fka Gritstone Oncology). Most recently, he developed robust processes and QC assays to enable manufacturability of a multi-edit, iPSC-derived, HER-2 targeting CAR-T at Fate Therapeutics.Abu received a BS in Biological Sciences from Cornell University in Ithaca NY and a PhD in Glycobiology from Albert Einstein College of Medicine in Bronx NY. As a new San Diegan, he cherishes the time spent in the garden and the canyon, experimenting with grafting, and propagating select plants.